8740 Visceral Adipose Tissue Assessment in Patients With Mild Autonomous Cortisol Secretion Using Dual-Energy X-Ray Absorptiometry: A Cross-Sectional Study

• DOI: 10.1210/jendso/bvae163.321
• Publication Date: 2024-10-05T20:00:07Z
• Authors: Jasmine Saini; Catherine D Zhang; Vanessa Fell; Elizabeth Atkinson; Sara Achenbach; Irina Bancos
• Keywords: Dual-Energy X-ray Absorptiometry; Dual energy

Abstract Disclosure: J. Saini: None. C.D. Zhang: V. Fell: E. Atkinson: S. Achenbach: I. Bancos: Background: Several studies employing computed tomography (CT) scans for body composition measurements have reported lower muscle mass and a higher proportion of visceral fat in patients with mild autonomous cortisol secretion (MACS) compared to referent subjects. While CT scan assesses adipose tissue (VAT) at single slice level (L3), no evaluated the overall VAT MACS using Dual-Energy X-ray absorptiometry (DXA). Objective: To determine impact on DXA as Methods: We conducted single-center cross-sectional study adults 75 was defined serum cortisol>1.8 mcg/dL after 1 mg dexamethasone suppression test adrenal adenomas features overt hypercortisolism. Referent subjects were included if they had abdominal imaging disorders. All participants underwent full between 04/2019 07/2022. applied CoreScan software estimate (1) total lean (2) volume (3) android, android mass, linear regression models adjusted sex BMI. Results: A (median age 57.0 years, IQR 47.8-65.6, 67% women) 57.6 49.1-65.8, included. Patients BMI 31.7 kg/m2, 27.4-37.9 vs 28.7, IQR, 25.4-33.8, P=0.004). The median post-DST 3.1 (IQR, 2.2-5.2). When subjects, adjustment BMI, similar (estimate=846, p-value=0.28) (estimate=-201, p-value=0.83), (estimate=59, p-value=0.64) but gynoid (estimate=400, 0.007). Notably, BMI-adjusted analysis also showed that (estimate= -225, p-value=0.084) mass/total ratio -0.007, p-value=0.026). Conclusions: sex, do not demonstrate differences mass. However, we is associated increased adiposity, known cardiovascular risk factor. Body assessment by could be safer less expensive alternative evaluation follow-up MACS. Presentation: 6/2/2024